Adjuvant Treatment of Malignant Melanoma
LACK OF EFFICACY OF ADJUVANT ISOLATED LIMB PERFUSION
Cheap generic viagra online
Isolated limb perfusion does not seem to have a role in the adjuvant treatment of patients who have high-risk melanoma of the limbs. In the recently completed EORTC/WHO adjuvant trial, patients with melanomas greater than 1.5 mm thick were randomized to WLE and observation or WLE and prophylactic hyperthermic isolated limb perfusion. A significantly decreased local recurrence rate was noted in the perfused population, but the distant disease-free survival and overall survival were the same. Thus, prophylactic perfusion using melphalan cannot be recommended.
ROLE OF ADJUVANT SYSTEMIC THERAPY FOR PATIENTS WITH MELANOMA AT HIGH RISK FOR RECURRENCE
Interferon
Advances in melanoma treatment over the past decade have evolved primarily from more detailed knowledge about prognostic factors of primary and metastatic lesions. Within the larger group of melanoma patients who undergo potentially curative treatment by surgical resection, subgroups can be identified who are at high risk for recurrence and for development of systemic metastases. Patients with melanomas 1.51 to 3.99 mm deep have a variable and intermediate risk of relapse, while patients with thick primary melanomas (more than 4 mm thick), in-transit lesions, and regional lymph node involvement are at particularly high risk: the 5-year relapse risk of these stage groupings generally exceeds 50%. Once distant metastases develop, median survival is only 6 to 9 months. The investigation of adjuvant systemic treatment that can prevent melanoma recurrence has become a critical area of investigation, focused upon either the intermediate or high-risk stage groups. The rationale and general principles for adjuvant treatment of cancer are based on the premise that treatment, whether chemotherapy or immunotherapy, is more effective when the tumor cell population is small and host immune and other resistance mechanisms are still intact. To date, randomized trials using dacarbazine, nitrosoureas, a variety of combination chemotherapy regimens, BCG, Corynebacterium parvum, transfer factor, and combinations of immunotherapy and chemotherapy have not demonstrated any advantage for treatment.
Adjuvant treatment for melanoma should be considered whenever possible within clinical research protocols that seek to improve on the results of current standard therapy in a systematic manner. Patients with a high risk of recurrence and death due to melanoma in the first several years following surgery include those patients with AJCC stage III melanoma (positive regional lymph node pathology) or those with deep primary invasion (greater than 4 mm Breslow depth). Patients in these two categories have at least a 50% chance of recurrence and death within 5 years of their diagnosis with just observation and are candidates for adjuvant trials. Investigations over the past decade have focused upon the interferons in this category of high-risk melanoma, and four trials conducted in this interval have recently been published or presented in national and international forums. The Eastern Cooperative Oncology Group has completed a trial of adjuvant therapy with high-dose IFN- alpha2b compared versus observation in stage IIb or III (AJCC) patients, the results of which have served as a pivotal basis for Food and Drug Administration (FDA) approval of IFN- alpha2b for the adjuvant treatment of high-risk melanomas. The treatment protocol adopted for this early trial is notable for its use of an initial month of daily intravenous therapy at 20 MU/m2 /d for 5 days a week for 4 weeks. This 1-month period of induction therapy was designed to deliver peak levels of circulating interferon- alpha unattainable by other routes, and was followed by 11 months of subcutaneous therapy at 10 MU/m2 three times a week, designed to sustain maximal tolerable levels of interferon in an outpatient or home therapy setting. An analysis of 280 of 287 patients for whom full data were available has demonstrated a significant prolongation of median time to relapse (1.7 versus 0.98 years, P2 = .005) and overall survival (3.8 versus 2.8 years, P2 = .047). Treatment was associated with an increment in the 5-year survival from 36% to 47%, and with an increment in the 5-year continuous relapse-free survival from 26% to 37%. These data have suggested the possibility of a curative impact of therapy with IFN- alpha2b as given in this trial. Cox multivariate analysis of this trial showed IFN therapy to be a highly significant independent prognostic factor and, after stage of disease, the most significant favorable prognostic factor.
Viagra professional online
Toxicity of this therapy is significant, with nearly ubiquitous flulike symptoms of moderate to severe degree, and the need for dose delay or attenuation in more than one-third of patients during induction, and again during the subcutaneous maintenance phase of treatment. The completion of 1 year of therapy was feasible in the majority (74%) of patients who did not experience progression. Proper attention to hematologic and hepatic function has been sufficient to avoid lethal hepatic toxicities observed early during the application of this intensive protocol. The ECOG has led an intergroup confirmatory sequel study (E1690/SWOG9111/CALGB9190) that completed accrual in mid-1995 and will require up to several years of maturity for evaluation. This protocol was designed not only to corroborate E1684 but also to test the influence of a lower dose of IFN- alpha2b, 3 MU/d given subcutaneously three times weekly for 2 years. It closed in 1995 with accrual of 642 patients. This Intergroup Trial differed from the initial trial E1684 in that lymph node dissection was no longer required for patients with T4 (greater than 4.0 mm) primary melanomas.